imatinib mesylate has been researched along with Abnormalities, Skin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baselga, E; Bernal, S; Bredrup, C; Gladkauskas, T; Iznardo, H; Mascaró, JM; Roé, E | 1 |
| Arteaga, CL; Roberts, RB; Threadgill, DW | 1 |
1 review(s) available for imatinib mesylate and Abnormalities, Skin
| Article | Year |
|---|---|
Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cardiomyoplasty; Colorectal Neoplasms; Cyclooxygenase 2; Disease Models, Animal; ErbB Receptors; Gastrointestinal Diseases; Genes, abl; Genetic Engineering; Humans; Imatinib Mesylate; Isoenzymes; Membrane Proteins; Mice; Mice, Transgenic; Neoplasms; Piperazines; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Transforming Growth Factor beta; Skin Abnormalities; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
1 other study(ies) available for imatinib mesylate and Abnormalities, Skin
| Article | Year |
|---|---|
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome.
Topics: Acro-Osteolysis; Dasatinib; Humans; Imatinib Mesylate; Limb Deformities, Congenital; Male; Progeria; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Skin Abnormalities; Young Adult | 2022 |